Integrated DNA, RNA and Whole-Blood Analysis Provides Deeper Molecular Insights for Precision Oncology
IRVING, Texas, Sept. 29, 2026 /PRNewswire/ -- Caris Life Sciences® (Caris), a leading AI TechBio company, today unveiled the enhanced Caris Assure®, a new evolution of liquid biopsy. By integrating Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS) and whole-blood analysis (for true CHIP identification) into a single platform, the enhanced Caris Assure assay provides a more complete molecular profile from a single blood draw, delivering deeper insights to help guide precision oncology decisions.
Read more at prnewswire.com